

1 MARGAWDF LCVLLLLLRV QTGSSQPSVS PGEPSPPSIH PGKSDLIVRV GDEIRLLCTD PGFVKWTFEI LDETENKQN
81 EWHITEAEAT NTGKYTCTNK HGLSNSIYVF VRDPAKLFLV DRSLYGKEDN DTLVRCPLTD PEVTNYSLKG CQGKPLPKDL
161 RFIPDPKAGI MIKSVKRAYH RLCLHCSVDQ EGKSVLSEKF ILKVRPAFKA VPVVSVSAS YLLREGEFT VTCTIKDVSS
241 SVYSTWKREN SQTQLQEKYN SWHGHDFNVE RQATLTISSA RVNDSGVFC YANNTFGSAN VTTTLEVVVK GFINIFPMIN
321 TTVFVNDGEN VDLIVEYEAFF PKPEHQQWIY MNRTFTDKWE DYPKSENE SN IRYVSELHT RLKGTEGTY TFLVNSDVN
401 AAIAFNVYVN TKPEILTYDR LVNGMLQCVA AGFPEPTIDW YFCPGTEQRC SASVLPVDVQ TLNSSGPPFG KLVVQSSIDS
481 SAFKHNGTVE CKAYNDVGKT SAYFNFAFKE QIHPTLFTP LLI GFVIVAG MMCIIVMILT YKYLQKPMYE VQWKVVEEIN
561 GNYYVYIDPT QLPYDHWKWEF PRNRLSFGKT LGAGAFGKVV EATAYGLIKS DAAMTVAVKM LKPSAHLTER EALMSELKVL
641 SYLGNHNMIV NLLGACTIGG PTLVITEYCC YGDLLNFLRR KRDSFICSKQ EDHAEALYK NLLHSKESCC SDSTNEYMDM
721 KPGVSYVVPT KADKRRSVRI GSYIERDVTP AIMEDDELAL DLEDLLFSY QVAKGMAFLA SKNCIHRDLA ARNILLTHGR
801 ITKICDFGLA RDIKNSNYV VKGNARLPVK WMAPESIFNC VYTFESDVWS YGIFLWELFS LGSSPYPGMP VDSKFYKMIK
881 EGFRMLSPEH APAEMYDIMK TCWDADPLKR PTFKQIVQLI EKQISESTNH IYSNLANCSP NRQKPVVDHS VRINSVGSTA
961 SSSQPLLVDH DV (SEQ ID NO: 1)

FIG. 1




FIG. 2C




FIG. 2B




FIG. 2A




FIG. 2E




FIG. 2D




FIG. 3B




FIG. 3A

4/33




FIG. 4




FIG. 5

6/33




FIG. 6




FIG. 8A

FIG. 8B




FIG. 8C

FIG. 8D




FIG. 8F




FIG. 8E

11/33




FIG. 8G




FIG. 8I





FIG. 8H



14/33




FIG. 8M




FIG. 8L

15/33




FIG. 8N





FIG. 9






FIG. 11




FIG. 12B




FIG. 12A




FIG. 12D




FIG. 12C

mAb1 ↓ 3 mg/kg ColdU									
Weeks	-2 (n=10)	0 (n=10)	1 (n=10)	2 (n=10)	4 (n=9)	6 (n=9)	8 (n=9)	12 (n=8)	
Phys-GA Mean (range)	2.3(2-3)	1.9(1-3)	0.6(0-1)	0.6(0-2)	0.4(0-1)	0.1(0-1)	0.2(0-1)	0.6(0-2)	
Pat-GA Mean (range)	1.7(0-3)	1.1(0-2)	0.4(0-1)	0.3(0-1)	0.1(0-1)	0.0	0.1(0-1)	0.3(0-2)	

FIG. 13A

mAb1 ↓ 3 mg/kg SD									
Weeks	-2 (n=9)	0 (n=9)	1 (n=9)	2 (n=9)	4 (n=9)	6 (n=9)	8 (n=8)	12 (n=6)	
Phys-GA Mean (range)	2.4(2-3)	2.0	1.8(1-2)	1	0.6(0-1)	0.4(0-1)	0.5(0-1)	0.7(0-2)	
Pat-GA Mean (range)	2.2(3-9)	2(1-3)	1.3(1-2)	1(0-2)	0.6(0-2)	0.2(0-1)	0.3(0-1)	0.8	

FIG. 13B

22/33




FIG. 14B




FIG. 14A




FIG. 14D

FIG. 14C




FIG. 15B




FIG. 15A




FIG. 15D




FIG. 15C




FIG. 16B




FIG. 16A




FIG. 16D




FIG. 16C




FIG. 17B




FIG. 17A

UCTScores ≥12	Predose	Week4	Week8	Week12
ColdU Patients % (n/N)	10%(1/10)	90%(9/10)	100%(10/10)	80%(8/10)
SD Patients % (n/N)	0%(0/10)	70%(7/10)	100%(9/9)	78%(7/9)
All Patients % (n/N)	5%(1/20)	80%(16/20)	100%(19/19)	79%(15/19)

FIG. 18A

UCT Score = 16	Predose	Week4	Week8	Week12
ColdU Patients % (n/N)	0%(0/10)	50%(5/10)	70%(7/10)	40%(4/10)
SD Patients % (n/N)	0%(0/10)	20%(2/10)	56%(5/9)	33%(3/9)
All Patients % (n/N)	0%(0/10)	35%(7/20)	63%(12/19)	37%(7/19)

FIG. 18B




FIG. 19B




FIG. 19A

≥ 4-point reduction* in DLQI from baseline *	Week4	Week8	Week12
ColdU Patients %(n/N)	100%(6/6)	100%(6/6)	83%(5/6)
SD Patients %(n/N)	88%(7/8)	86%(6/7)	86%(6/7)
All Patients %(n/N)	93%(13/14)	92%(12/13)	85%(11/13)

FIG. 20A

DLQI score = 0-1†	Week4	Week8	Week12
ColdU Patients %(n/N)	56%(5/9)	70%(7/10)	67%(6/9)
SD Patients %(n/N)	60%(6/10)	67%(6/9)	44%(4/9)
All Patients %(n/N)	58%(11/19)	68%(13/19)	56%(10/18)

FIG. 20B

32/33

TempTest and FricTest Over Time in ColdU and SD Patients




FIG. 21A




FIG. 21B